Skip to content
Buy This GLP
← Research
Evidence

Do You Take a GLP-1 Before or After Bariatric Surgery?

Before surgery, a records study examined early heart and kidney events. After surgery, trials tested whether medication could help people who lost less weight than expected.

Editorial profile: Neil SandersBuy This GLP Editorial Team4 min read
Events in 90 days, 11,052 patients per groupcardiovascular events36 prior prescription (0.3%)67 without prior use (0.6%)kidney events158 prior prescription (1.4%)256 without prior use (2.3%)Groups matched using medical records

Whether a GLP-1 is used before or after bariatric surgery depends on what the care team is trying to achieve. One study examined heart and kidney complications after surgery in patients with a prior prescription. Other studies examined weight loss when medication was added after the operation. Guidance about GLP-1 use around anesthesia answers a separate question about safety during a procedure.[1][2][4][5]

What the preoperative study found

Researchers matched 11,052 patients with a prior GLP-1 or tirzepatide prescription to 11,052 without one. The researchers counted events over the first 90 days after surgery. The major cardiovascular composite occurred in 36 prior users (0.3%) and 67 controls (0.6%). The hazard ratio was 0.535 (95% CI 0.357–0.803). Kidney events occurred in 158 prior users (1.4%) and 256 controls (2.3%).[1]

Prior use meant a prescription 7 to 365 days before the operation. The researchers excluded prescriptions closer to surgery. Prescription dates cannot establish when patients last took medication. Matching cannot account for every difference between patients. The study cannot establish that treatment before surgery prevents these complications.[1]

What studies found after surgery

A study of semaglutide after sleeve gastrectomy included 103 patients. Treatment began one month after surgery and continued through month six. At one year, the semaglutide group had lost 35.14% of its preoperative weight. The surgery-only group had lost 30.73%. The study did not randomly assign treatment.[2]

A systematic review examined treatment after weight regain or limited weight loss. At 12 months, separate analyses for semaglutide and liraglutide each estimated roughly 9% weight loss. The estimates varied substantially across studies. The randomized BARI-STEP trial enrolled adults at least one year after bypass or sleeve surgery. They had lost less than 20% of their body weight. Over 68 weeks, the semaglutide group lost about 19 percentage points more than the placebo group. These estimates come from different populations and study designs.[3][4]

Ask your bariatric team and prescribing clinician to coordinate any medication changes. The American Society of Anesthesiologists says most patients can continue before a procedure. It advises individual planning when risks are higher.[5]

Frequently asked

Is a GLP-1 used before or after bariatric surgery?
Both have been studied for different purposes. The preoperative cohort measured early complications, while postoperative trials evaluated additional weight loss in selected patients. Medication timing depends on the reason for treatment and the surgical plan.
How soon after bariatric surgery did the studies start treatment?
One nonrandomized sleeve gastrectomy study started semaglutide at one month. The randomized BARI-STEP study enrolled selected patients at least one year after surgery. Neither establishes a start date for every patient.

Sources

  1. [1] Tseng TC, Chang R (2026). Prior GLP-1RA or Tirzepatide Use and Early Cardiorenal Outcomes After Metabolic and Bariatric Surgery The American Journal of Medicine. PMID 42735883
  2. [2] Huang YS, Wen J, Wang S, Song Y, Zhou B, Zhang N, Meng H (2026). Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study Obesity Surgery. PMID 42174244
  3. [3] Santos-Pereira M, et al. (2026). Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis Frontiers in Endocrinology. PMID 42718598
  4. [4] Stanley C, Mallik R, Hamid N, et al. (2026). Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial Nature Medicine. PMID 42174253
  5. [5] American Society of Anesthesiologists (2025). Drugs for Diabetes or Weight Loss: What To Know Before Surgery American Society of Anesthesiologists. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence